TALLINN, Estonia, Oct. 11, 2016 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced today that it has opened a pharmaceutical Product Development laboratory in Estonia. The GMP-compliant lab will support the development of topical and injectable pharmaceutical products for the company’s North American markets.
The 3,000-square foot facility also includes administrative space for quality assurance and supply chain employees who oversee the company’s third-party contract manufacturing activities around the world.
“We are excited to strengthen our R&D capabilities through the opening of this product development lab in Estonia,” commented Jason Grenfell-Gardner, President and CEO of the Company. “We are impressed by the caliber of scientific talent available in the country, and look forward to this lab working closely with our R&D colleagues in New Jersey.’'
The Company established its operation in Estonia in 2015, where it has been managing logistics and supply relationships between third-party suppliers and the US and Canadian markets. Grenfell-Gardner concluded, ''The opening of this lab for analytical method and formulation work is the next step in our journey to build pharmaceutical capabilities in our Estonia business.’'
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Forward-Looking Statements
This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as “plan,” “believe,” “continue,” “should” or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in Teligent, Inc.'s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission. Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
Contact: | Jenniffer Collins |
Teligent, Inc. | |
(856) 697-4379 | |
Logo - http://photos.prnewswire.com/prnh/20151022/279641LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/teligent-inc-announces-the-opening-of-a-product-development-laboratory-in-estonia-300342365.html
SOURCE Teligent, Inc.
